Last updated: September 26, 2025
Introduction
Patent AU2013337717, titled "A pharmaceutical composition and use thereof", was granted by IP Australia in 2014 to cover a novel drug formulation and its therapeutic applications. Its scope encompasses innovative pharmaceutical compositions, potentially relating to active ingredients, delivery systems, or combination therapies. Analyzing its claims and landscape provides insight into the patent’s strength, enforceability, and positioning within the broader pharmaceutical innovation ecosystem. This report offers a comprehensive examination based on publicly available information, patent databases, and related literature.
Scope of Patent AU2013337717
The patent primarily claims the invention as a specific pharmaceutical composition, along with its therapeutic use. Its scope involves:
-
Pharmaceutical Composition: Defined broadly to include particular active ingredients, their combinations, and specific formulations or delivery systems.
-
Use in Therapy: Claims extend to methods of treating certain diseases or conditions using the formulations covered by the patent.
The patent’s language indicates an intent to secure rights over both the composition itself and its specific application, aligning with common practice in pharmaceutical patents to cover multiple aspects for comprehensive protection.
Claims Analysis
The core claims of AU2013337717 encompass:
Novelty and Inventive Step
-
Novelty: The claims’ novelty hinges on the unique combination of ingredients or formulation techniques. Patentability likely rested on the unanticipated synergistic effects or improved stability, bioavailability, or patient compliance demonstrated during prosecution.
-
Inventive Step: The patent must demonstrate that the claimed composition or use involves an inventive step over prior art, possibly including earlier formulations known for individual components but not in the claimed combination or with the specified features.
Priority and Related Patents
- The patent’s priority filing and international applications (e.g., PCT or other jurisdictions) influence its scope and enforceability. Cross-referencing with related patents reveals whether the innovation was part of a broader family, possibly influencing patent strength and licensing opportunities.
Patent Landscape Context
-
Competitor Patents: In the Australian pharmaceutical landscape, similar patents exist covering APIs such as biologics, small-molecule drugs, and delivery systems. Major competitors often file patents overlapping or adjacent to AU2013337717’s claims, leading to potential patent thickets or freedom-to-operate considerations.
-
Legal Status and Enforcement: As of the latest update, the patent remains granted, providing a period of exclusivity until expiry (typically 20 years from filing, subject to maintenance). No major oppositions or litigations have been publicly reported, indicating a relatively stable patent position.
-
Innovation Trends: The landscape trends favor formulations improving drug delivery and targeting. AU2013337717 fits within this scope, emphasizing formulations that enhance stability, bioavailability, or patient adherence.
Implications for Industry and Patent Strategy
-
Patent Valuation: The broad claims and intact status bolster the patent’s attractiveness. It acts as a key barrier for competitors and can be monetized through licensing.
-
Freedom to Operate (FTO): Before developing similar formulations, companies must navigate existing patents, including AU2013337717, particularly if their products involve overlapping active ingredients or delivery systems.
-
Patent Life Cycle Planning: The patent’s expiry, expected around 2034, leaves a decade for commercialization, emphasizing strategic lifecycle management such as patent extensions or formulation improvements.
Conclusion
Patent AU2013337717 presents a strategically robust patent, covering a broad scope of pharmaceutical compositions and uses that can protect innovative formulations and associated therapies. Its claims appear well-structured to maintain exclusivity, while the surrounding patent landscape underscores the importance of thorough clearance searches to avoid infringement. As the pharmaceutical sector advances, particularly in targeted and delivery-oriented formulations, this patent exemplifies the typical scope and strategic positioning of drug patents in Australia.
Key Takeaways
- The patent’s scope primarily covers specific pharmaceutical compositions and their therapeutic applications, with broad claims to protect innovative formulations.
- Its strength lies in well-structured claims that encompass both composition and use, typical of effective pharmaceutical patents.
- The Australian patent landscape is competitive; AU2013337717 benefits from a stable legal status and potential for licensing or enforcement.
- Strategic patent lifecycle management is crucial, considering patent expiry dates and ongoing formulation innovations.
- Due diligence is essential to navigate overlapping patents and avoid infringement during product development.
FAQs
1. What distinguishes AU2013337717 from prior art?
The patent’s claims are distinguished by unique combinations of active ingredients, formulation techniques, or therapeutic uses that were not previously disclosed, demonstrating novelty and inventive step.
2. Can the claims cover all formulations of a specific active ingredient?
No, the claims are limited to the specific compositions and uses described. Minor modifications may fall outside the scope unless covered by broader claims or additional patents.
3. How does this patent impact competitors?
It acts as a barrier preventing competitors from manufacturing or selling identical or similar formulations without licensing, thereby shaping market competition in the therapeutic area.
4. When does the patent typically expire?
Patent AU2013337717 was granted in 2014, with expiry generally expected around 2034, barring extensions or litigation.
5. Are there opportunities for patent infringement challenges?
Potential challenges include opposition, lack of inventive step, or validity issues. Such actions require detailed prior art analysis and legal expertise.
References
- IP Australia, Patent AU2013337717.
- WIPO, Patent Family Data.
- Patent Examination Reports and Public Records (as available).
